On Friday, NewAmsterdam Pharma Company NV (NASDAQ: NAMS) opened lower -12.17% from the last session, before settling in for the closing price of $18.00. Price fluctuations for NAMS have ranged from $15.19 to $27.29 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 34.27% over the last five years. Company’s average yearly earnings per share was noted 29.96% at the time writing. With a float of $57.00 million, this company’s outstanding shares have now reached $108.06 million.
The firm has a total of 68 workers. Let’s measure their productivity. In terms of profitability, gross margin is 99.96%, operating margin of -370.98%, and the pretax margin is -512.33%.
NewAmsterdam Pharma Company NV (NAMS) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of NewAmsterdam Pharma Company NV is 48.10%, while institutional ownership is 48.02%. The most recent insider transaction that took place on Mar 26 ’25, was worth 25,521. In this transaction Director of this company bought 1,135 shares at a rate of $22.49, taking the stock ownership to the 3,013,569 shares. Before that another transaction happened on Mar 26 ’25, when Company’s Affiliate proposed sale 12,258 for $23.41, making the entire transaction worth $286,960.
NewAmsterdam Pharma Company NV (NAMS) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.42 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 29.96% per share during the next fiscal year.
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Trading Performance Indicators
Check out the current performance indicators for NewAmsterdam Pharma Company NV (NAMS). In the past quarter, the stock posted a quick ratio of 8.08. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 38.11.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.60, a number that is poised to hit -0.50 in the next quarter and is forecasted to reach -1.84 in one year’s time.
Technical Analysis of NewAmsterdam Pharma Company NV (NAMS)
Analysing the last 5-days average volume posted by the [NewAmsterdam Pharma Company NV, NAMS], we can find that recorded value of 1.79 million was better than the volume posted last year of 0.95 million. As of the previous 9 days, the stock’s Stochastic %D was 9.05%. Additionally, its Average True Range was 1.45.
During the past 100 days, NewAmsterdam Pharma Company NV’s (NAMS) raw stochastic average was set at 3.20%, which indicates a significant decrease from 4.19% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.88% in the past 14 days, which was lower than the 81.13% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $21.21, while its 200-day Moving Average is $20.10. Now, the first resistance to watch is $17.40. This is followed by the second major resistance level at $18.98. The third major resistance level sits at $19.97. If the price goes on to break the first support level at $14.83, it is likely to go to the next support level at $13.84. Now, if the price goes above the second support level, the third support stands at $12.26.
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Key Stats
There are currently 109,818K shares outstanding in the company with a market cap of 1.74 billion. Presently, the company’s annual sales total 45,560 K according to its annual income of -241,600 K. Last quarter, the company’s sales amounted to 12,770 K and its income totaled -92,180 K.
